novo nordisk weight loss drug - Search News

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.

Hosted on MSN · 1d

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Barron's on MSN · 1d

Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.

Yahoo Finance13d

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product ...

The weight-loss drugs being tested in 2025: will they beat Ozempic?

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

1d

Weight loss pill could replace injections, would be transformative for millions

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

2don MSN

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns.

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results